Melanoma Clinical Trials in Baltimore

Showing 261-280 of 320 trials

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337

To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer

Carcinoma, Non-Small-Cell LungColorectal CancerMalignant Melanoma+2 more

Bristol-Myers Squibb39 participantsStarted Aug 2006

Baltimore, Maryland, United States • Detroit, Michigan, United States • St Louis, Missouri, United States +1 more locations

COMPLETEDPhase 134 miles

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

NCT00005057

RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.

Melanoma (Skin)

National Human Genome Research Institute (NHGRI)Started Mar 2000

Bethesda, Maryland, United States • Bethesda, Maryland, United States • Houston, Texas, United States

COMPLETEDPhase 234 miles

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

NCT01014351

Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.

Metastatic Melanoma

SCRI Development Innovations, LLC70 participantsStarted Feb 2010

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Evansville, Indiana, United States +9 more locations

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Melanoma Trials in Other Cities

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Baltimore